The Fund invested in BioVercys 32,6M CHF = 35M UD$ and got perhaps 10%-15% (?) of the company. Today the market cap of ATH was US$16,38M, much less than it has cash and also much less than what the investment by the Fund was to get 10-15 % (?) of BioVercys.
I do not think the experts of the Fund made any big mistake when they evaluated the value of that company. I would expect the corresponding valuation when and if the Fund evaluates PBT2 and ATH as a possible investments.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
0.006(66.7%) |
Mkt cap ! $136.9M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.5¢ | 1.0¢ | $1.185M | 92.95M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 742856 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 4020492 | 17 |
View Market Depth
| Last trade - 16.10pm 11/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |